Labarge v. Elutia, Inc.

District Court, S.D. California·Decided July 21, 2025·No. 3:24-cv-01857·Unknown

Opinion

WILLIAM LABARGE, et al. Case No. 24-cv-1857-MMA-DEB

Plaintiffs, ORDER GRANTING PLAINTIFFS’ v. MOTION TO AMEND THE COMPLAINT ELUTIA, INC., formerly known as Aziyo Biologics, Inc., et al., [Doc. No. 75] Defendants. On May 9, 2025, Plaintiffs William and Carol Labarge (collectively “Plaintiffs”) filed a motion to amend their complaint against Defendants Elutia, Inc. f/k/a Aziyo Biologics, Inc. (“Aziyo”) and DCI Donor Services, Inc. d/b/a Tennessee Donor Services (“DCI”; collectively “Defendants”). Doc. No. 75. DCI filed a response in opposition, with which Aziyo joined and to which Plaintiffs replied.1 Doc. Nos. 88–90. On June 30, 2025, The Court found this matter suitable for determination on the papers and without oral argument pursuant to Federal Rule of Civil Procedure 78(b) and Civil Local Rule 7.1.d.1 and took the hearing off calendar accordingly. Doc. No. 91. For the following reasons, the Court GRANTS Plaintiffs’ motion to amend the complaint.

1 Because Aziyo filed a notice of joinder to DCI’s opposition, see CivLR 7.1.j, the Court refers to the Plaintiffs filed their initial complaint on October 15, 2024, asserting claims for: negligence, strict liability, breach of implied warranty, and breach of express warranty against Aziyo; negligence against DCI; and loss of consortium against both Aziyo and DCI. Doc. No. 1 (“Compl.”) ¶¶ 56–97. These claims arise from allegations that, in summary, Plaintiff William LaBarge received a defective spinal implant, manufactured by Aziyo and DCI, that exposed him to tuberculosis and caused him illness, injury, and continued pain.2 Id. ¶¶ 16–55. Plaintiffs now seek to amend the complaint to reflect: (1) amended causes of action;3 and (2) a prayer for punitive damages supported by new allegations that both Aziyo and DCI accepted “donors with diagnoses of sepsis during their terminal hospitalization . . . for harvesting in willful and conscious disregard for the safety of others.” See Doc. No. 75-1 (“PFAC”) ¶¶ 68, 77. As to the new allegations, Plaintiffs assert that Defendants both used Aziyo’s “SOP-0006”4 to determine donor eligibility. Id. ¶ 29. During inspections of Aziyo in or around September 2023, the FDA purportedly noted: (1) . . . that between June 1, 2022[,] and January 31, 2023, multiple donors with sepsis diagnoses were deemed eligible for donation[;] (2) that [Aziyo’s] SOP-0006 was not designed to ensure compliance with donor eligibility requirements[;] (3) complete set of medical records were not made available to the medical director prior to donor eligibility determination when multiple donors had a recent diagnosis of sepsis[;] and (4) personnel authorization to perform designated function related to donor eligibility determinations were not qualified through appropriate medical treating to review clinical evidence consistent with risks for sepsis.

2 Plaintiffs allege, specifically, that Aziyo manufactures the implant, and “retained DCI to, among other things, procure and provide the cadaveric tissue it used . . . .” Compl. ¶¶ 16–23. 3 The proposed amended causes of action are: (1) negligence against Aziyo; (2) negligence against DCI; and (3) loss of consortium, which Plaintiffs appear to bring against both Defendants. PFAC ¶¶ 63–81. Id. ¶ 31. Plaintiffs further plead that after inspecting DCI during the same timeframe: the FDA made multiple observations including: (1) DCI failed to verify that the donor screening procedures it was utilizing were consistent with current donor eligibility requirements pertaining to donor diagnosed with sepsis or clinical evidence of infection[;] and (2) Between January 2, 2022[,] and September 5, 2023, DCI screened, determined to be suitable for recovery, recovered[,] and released for shipment under quarantine approximately 99 donors diagnosed with sepsis in medical records during a hospital stay immediately preceding death.

Id. ¶ 32. “Neither Aziyo or DCI expressly warned users, customers, physicians or the medical community that its Donor Selection Standard Operating Procedures were in violation of AATB[5] standards and FDA Guidelines[]” or that that they “accepted donors with evidence of Sepsis during terminal hospitalization.” Id. ¶¶ 33–34. Plaintiffs allege that the donor for William LaBarge’s implant had active tuberculosis and “sepsis during his hospital stay immediately preceding death . . . .” Id. ¶ 39–40. Despite this, “the donor was cleared and accepted for harvesting by both DCI and [Aziyo].” Id. ¶ 40. II. LEGAL STANDARD Federal Rule of Civil Procedure 15 generally governs amendments to pleadings. Fed. R. Civ. P. 15. However, once a district court has issued a scheduling order under Rule 166 establishing a timetable for amending pleadings, Rule 15’s standards no longer govern should a party seek amendment after the scheduling order’s deadline to do so. See Johnson v. Mammoth Recreations, Inc., 975 F.2d 604, 607–09 (9th Cir. 1992); Sharp v. Balboa Islands, LLC, No. 11-CV-427, 2012 WL 13176036 *2–3 (S.D. Cal. Jun. 20, 2012). Instead, the moving party must meet Rule 16’s requirement to modify the schedule. Id. Under Rule 16, “[a] schedule may be modified only for good cause and with the judge’s consent.” Fed. R. Civ. P. 16(b)(4). In this context, good cause is

Free access — add to your briefcase to read the full text and ask questions with AI

Labarge v. Elutia, Inc., (S.D. Cal. 2025).

Labarge v. Elutia, Inc. (Labarge v. Elutia, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Erie Railroad v. Tompkins
304 U.S. 64 (Supreme Court, 1938)
Hanna v. Plumer
380 U.S. 460 (Supreme Court, 1965)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Jackson v. East Bay Hospital
980 F. Supp. 1341 (N.D. California, 1997)
Vallbona v. Springer
43 Cal. App. 4th 1525 (California Court of Appeal, 1996)
Goodstein v. Superior Court
42 Cal. App. 4th 1635 (California Court of Appeal, 1996)
Treadwell v. Himmelmann
50 Cal. 9 (California Supreme Court, 1875)
Wray v. Gregory
61 F.3d 1414 (Ninth Circuit, 1995)
Estate of Prasad ex rel. Prasad v. County of Sutter
958 F. Supp. 2d 1101 (E.D. California, 2013)
Richardson v. United States
841 F.2d 993 (Ninth Circuit, 1988)
Moore v. Kayport Package Express, Inc.
885 F.2d 531 (Ninth Circuit, 1989)